Kyowa Kirin Co., Ltd.
4151.THealthcareTSEDrug Manufacturers - Specialty & Generic
Scan Results
Daily timeframeKyowa Kirin Co., Ltd. engages in the research, development, manufacturing, and marketing of pharmaceuticals in Japan, the Americas, Europe, Asia, and internationally. Valued at $1.33T, 4151.T is a mega-cap name in its sector. The company offers Ziftomenib, an oral menin inhibitor for the treatment of adult relapsed or refractory and acute myeloid leukemia with a nucelophosmin1 mutation; and Lumicef for the treatment of palmoplantar pustulosis.
Market Cap
$1.33T
Beta
0.10
P/E (TTM)
19.88
P/E (Fwd)
18.34
EPS (TTM)
$128.00
EPS (Fwd)
$138.74
ROE
8.5%
ROA
6.6%
Cash
$249.52B
Total Debt
$0
Free CF
$36.55B
52W Change
4.6%
Annual Financials
Cash vs Debt
Kyowa Kirin Co., Ltd. reports $249.52B in cash and $0 in total debt. The company generates $36.55B in free cash flow annually, which funds everything from R&D to shareholder returns without needing external financing. ROE of 8.5% points to decent capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. An ROA of 6.6% suggests reasonable efficiency in deploying the company's asset base. Revenue has grown from $352.25B (2021) to $496.83B (2025), reflecting a 41% increase over the period.
The relatively low beta of 0.10 suggests 4151.T is a less volatile holding compared to the broader index. No single metric tells the full story. Reviewing 4151.T's risk profile alongside its fundamentals and technical indicators provides a more complete picture.